Does Ivosidenib work?

Ivosidenib (Ivosidenib) is a targeted treatment for acute myeloid leukemia (AML). It is mainly used for AML patients expressing IDH1 gene mutations. The following will be combined with some clinical experimental data to explore the efficacy of ivonib.

Overview of clinical trial results:

1.Pivotal clinical trials: A pivotal clinical trial is AGILE (AG221-C-001), which investigated the safety and efficacy of ivonib in the treatment of patients with IDH1mutated AML. The trial was a multicenter, open-label clinical trial that included patients of different ages and prior treatment experience.

2.Effectiveness data: Trial results show that in AML patients using ivonib, the IDH1 gene mutation in the leukemia cells of many patients has been significantly controlled. Studies have also shown that treatment with ivonib can lead to improved remission rates in AML patients, with some patients even achieving complete remission.

3.Survival analysis: In some studies, AML patients treated with ivonib showed longer overall survival compared with the traditional treatment group. This suggests that ivonib has a positive impact on improving the long-term survival of AML patients.

Research Highlights and Discussion:

1.Specific effect: Avonib acts asIDH1Inhibitors are highly specific and mainly act on AML patients expressing mutations in the IDH1 gene. This specific effect reduces the adverse effects on normal cells and improves the safety of treatment.

2.Advantages of targeted therapy: Avosidenib represents a successful case of targeted therapy strategy. Compared with traditional chemotherapy, targeted therapy is more precise, helps reduce damage to healthy cells, and reduces discomfort during treatment.

3.Personalized treatment: Clinical trial data emphasize the importance of individualized treatment. By testing patients forIDH1 gene mutations, doctors can more accurately determine which patients can benefit from treatment with ivonib, thereby achieving a more personalized treatment plan.

Potential side effects and safety issues:

1.Electrocardiogram changes: Some clinical trials have found that patients using ivonib may experience electrocardiogram changes, including prolongation of the QT interval. Therefore, regular ECG monitoring is usually required during treatment to ensure that the patient's heart is functioning properly.

2.Abnormal liver function: The use of ivonib may also cause abnormal liver function. Therefore, doctors regularly monitor patients' liver function indicators to detect and deal with any potential problems in a timely manner.

Avosidenib has shown significant therapeutic effects in clinical trials on AML patients with IDH1 gene mutations. As a targeted therapy drug, it provides more precise treatment options for AML patients, improves the patient's remission rate and survival period, and reduces some side effects related to traditional chemotherapy. However, patients should be closely monitored for potential side effects while using ivosidenib and maintain good communication with their doctor to ensure optimal treatment results.

Avosidenib is already on the market in China, but it has not yet been included in medical insurance. The price of Avosidenib on the domestic market is very high, reaching tens of thousands of yuan. For specific prices, please consult the local hospital pharmacy. The price of the American original drug of Ivonib abroad is as high as hundreds of thousands. Currently, there are generic drugs of Ivonib on the market, mainly Laos generic drugs, which cost about 10,000 yuan, which is much cheaper in comparison, and the ingredients of the original drug and the generic drug are basically the same.